Voyager Therapeutics, Inc. (VYGR)
After hours:
| Previous close | 8.53 |
| Open | 8.76 |
| Bid | 8.79 x 100 |
| Ask | 8.83 x 300 |
| Day's range | 8.61 - 8.92 |
| 52-week range | 6.06 - 14.34 |
| Volume | |
| Avg. volume | 658,990 |
| Market cap | 479.161M |
| Beta (5Y monthly) | 0.95 |
| PE ratio (TTM) | 2.97 |
| EPS (TTM) | 2.97 |
| Earnings date | 07 May 2024 - 13 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 17.78 |
ZacksAgios (AGIO) Q1 Earnings Surpass, Sales Miss Estimates
Agios (AGIO) reports mixed earnings results for first-quarter 2024. Though sales miss the mark, revenues from its sole marketed drug, Pyrukynd, rise sequentially and on a yearly basis.
- Zacks
Jazz (JAZZ) Q1 Earnings & Sales Fall Short of Estimates
Jazz's (JAZZ) first-quarter earnings and sales miss the mark. The company reaffirms its guidance for full-year 2024.
GlobeNewswireVoyager Therapeutics to Present Broad Set of Translational Data Supporting IV-Delivered, CNS Gene Therapy Programs Advancing Toward Clinical Trials at the ASGCT 27th Annual Meeting
Spotlight on new, second-generation, TRACER™-derived AAV capsids; translatability as evidenced by cross-species and receptor data; and activity against therapeutic targets in Alzheimer’s disease and ALSLEXINGTON, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that it will present a broad set of data related to its TRACER™ capsid discovery platform and TRACER-driven gene th
